---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-042414"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T13:29:39.821995+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Heron Therapeutics Q2 2023 revenue up; secures $80M in new financing; cost cuts expected to save $75M through 2025

## Summary
- Oncology care franchise net product sales $27.3M (Q2 2023) vs $25.1M (Q2 2022); acute care franchise sales $4.5M vs $2.5M.
- Full-year 2023 oncology care net product sales guidance reiterated at $99M-$103M.
- Closed $29.7M equity placement in July 2023; entered $50M working capital facility in August 2023 with $24.5M drawn.
- Cost reduction program expected to save ~$75M in cash spend through 2025; new management team in place.
- Favorable Markman hearing outcome in CINVANTI patent litigation against Fresenius Kabi.

## SEC filing metadata
- accession: 0000950170-23-042414
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000095017023042414/0000950170-23-042414-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000095017023042414/hrtx-20230814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-042414
- JSON: https://secwatch.observer/filing/0000950170-23-042414.json
- Plain text: https://secwatch.observer/filing/0000950170-23-042414.txt

## Key facts
- Earnings Releases
  HERON THERAPEUTICS, INC. /DE/ updated its the three and six months ended June 30, 2023 guidance (reaffirmed).
  - Period: the three and six months ended June 30, 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: On August 14, 2023, Heron Therapeutics, Inc. (“Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/818033/000095017023042414/0000950170-23-042414-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.